Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The Parkinson’s disease (PD) therapy market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND-0612, AP-CD/LD, IPX-203); two new rescue therapies for “off” periods are or soon will be available (i.e., Inbrija, APL-130277); and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B-001, HP-3000). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales of PD therapies. However, given the cost-sensitivity of PD patients and the widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 28 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.
Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.
Emerging therapies: Phase II: 29 drugs; Phase III: 6 drugs; preregistration: 2 drugs. Coverage of select preclinical and Phase I products.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key PD therapies through 2027, segmented by brands/generics.
Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, UCB, US WorldMeds, Zambon Pharma.
Key drugs: levodopa, amantadine, apomorphine, AP-CD/LD, APL-130277, Duodopa/Duopa, entacapone, Gocovri, HP-3000, IPX-203, ND-0612, Neupro, Nouriast, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B-001, rasagiline, ropinirole, Rytary/Numient, selegiline, Trerief, Xadago.
Already a Client? Log in to access this report.
Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.